DEFR14A: Azenta Shareholders to Vote on Directors, Equity Plan Boost

Azenta, Inc. announces its 2026 Annual Meeting of Shareholders agenda, including the election of ten directors, an advisory vote on executive compensation, and a proposal to increase shares for its 2020 Equity Incentive Plan by 2,750,000.

Summary

• The Annual Meeting of Shareholders will be held virtually on Wednesday, January 28, 2026, at 9:00 a.m. Eastern Time.
• Shareholders will vote on the election of ten directors, an advisory resolution on executive compensation, and a proposal to amend the 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 2,750,000.
• PricewaterhouseCoopers LLP is proposed for ratification as the company's independent registered accounting firm for the 2026 fiscal year.
• Fiscal year 2025 saw reported revenue growth of 4% to $594 million, with organic growth at 3%.
• Adjusted EBITDA from Continuing Operations reached $66 million, representing an 11.2% margin, up 310 basis points year-over-year.
• Adjusted Operating Income was $16 million, with a margin of 2.6%, up 200 basis points year-over-year.
• Free Cash Flow improved significantly to $38 million, a $26 million increase over the prior year.
• The company identified material weaknesses in its internal control over financial reporting for fiscal years 2024 and 2025, with remediation plans underway.
• A clawback of $56,116 in erroneously awarded FY2024 incentive compensation was initiated due to revisions in financial statements.
• The FY2023-2025 Long-Term Incentive Plan (LTIP) resulted in 0% achievement due to performance below threshold on all three metrics.

Sentiment

Score: 7

Explanation: The filing presents a mixed but generally positive outlook. While there are clear financial improvements (revenue growth, margin expansion, FCF), and strong governance practices, the 0% achievement on the prior LTIP and the identified material weaknesses in internal controls introduce a degree of caution. The proposed equity plan increase and strategic focus on core businesses are positive for future growth.

Positives

• Strong fiscal 2025 financial performance with 4% reported revenue growth and 3% organic growth.
• Significant margin expansion, with Adjusted EBITDA margin increasing by 310 basis points to 11.2%.
• Improved Free Cash Flow of $38 million, marking a $26 million improvement over the prior year.
• Strategic decision to reclassify and pursue the sale of the B Medical business to streamline the portfolio and accelerate growth in core businesses.
• High shareholder approval (over 99%) for the 2025 say-on-pay proposal, indicating alignment with executive compensation philosophy.
• Introduction of Relative Total Shareholder Return (rTSR) as the sole performance metric for Performance Share Units (PSUs) in the LTIP, enhancing alignment with shareholder interests.
• Robust corporate governance practices, including a majority independent board (9 out of 10 nominees), separate Board Chair and CEO roles, and annual board evaluations with independent third-party assistance.
• Commitment to diversity, with 40% of director nominees representing gender, racial, or ethnic diversity.
• Maintenance of a strong cash position of $546 million at fiscal year-end.
• Implementation of a clawback policy and insider trading policy prohibiting hedging, pledging, and short sales of company stock.

Negatives

• Identified material weaknesses in internal control over financial reporting for fiscal years 2024 and 2025, specifically related to classification of certain costs and account reconciliations.
• A clawback of $56,116 in erroneously awarded FY2024 incentive compensation was required due to financial statement revisions negatively impacting performance goals.
• The FY2023-2025 Long-Term Incentive Plan (LTIP) achieved 0% of target, falling below threshold performance on all three metrics (cumulative Adjusted EBITDA, cumulative Free Cash Flow, and three-year average ROIC).
• Core Revenue for the FY2025 Incentive Compensation Plan (ICP) came in below target at 85.8% performance.
• Adjusted EBITDA performance for the FY2025 ICP was slightly below target at 94.1%.

Risks

• Material weaknesses in internal control over financial reporting, specifically concerning the classification of certain costs in the Consolidated Statement of Operations and the preparation and review of account reconciliations, could lead to future financial misstatements.
• The company operates in cyclical and volatile industries, which could impact future financial performance.
• Failure to attract and retain exceptional talent is a risk to advancing the company's strategy and achieving long-term success.
• Risks associated with mergers, acquisitions, and divestitures, including the ongoing sale of the B Medical business, could impact financial results and operational focus.
• Cybersecurity and data privacy risks are core operational pillars requiring continuous management and compliance.
• Compliance and regulatory matters, including adherence to SEC and Nasdaq rules, pose ongoing risks.

Future Outlook

The company aims to continue accelerating revenue growth and profitability in its core businesses by streamlining its portfolio, as evidenced by the reclassification and planned sale of its B Medical business. The executive compensation program is designed to drive sustainable growth and long-term shareholder returns, with new LTIP metrics focused on Relative Total Shareholder Return over a three-year period. The proposed increase in shares for the equity incentive plan is expected to provide sufficient authorization for anticipated stock-based awards for the next four years, supporting talent attraction and retention.

Management Comments

• Our executive compensation program reflects Azenta's commitment to innovation, growth, and delivering value for our customers, employees, and shareholders.
• Attracting and retaining exceptional talent is essential to advancing our strategy and achieving long-term success.
• Fiscal 2025 was a transformative year for Azenta. We delivered 4% reported revenue growth and 3% organic growth, alongside significant margin expansion of 310 basis points.
• The results were driven by business simplification through the Azenta Business System, and enhanced execution, which led to measurable improvements in quality, delivery, and productivity.
• We reclassified our B Medical business to discontinued operations and are pursuing its sale to streamline our portfolio and accelerate revenue growth and profitability in our other core businesses.
• We believe that the effective use of stock-based long-term incentive compensation is important to our continued growth and success by incentivizing performance, helping us meet our retention needs, delivering competitive compensation programs, and in general aligning the interests of our key employees, consultants and directors with those of our stockholders.

Industry Context

Azenta operates in the life sciences industry, providing sample exploration and management solutions. The company's strategic decision to divest its B Medical business and focus on core life sciences areas (Sample Management Solutions and Multiomics) aligns with a trend towards specialization and optimizing portfolios for higher growth and profitability within the dynamic life sciences sector. The adoption of Relative TSR as a key compensation metric reflects an increasing focus on shareholder value creation and competitive performance against industry peers, indicating a move towards best practices in executive incentive alignment within the industry.

Comparison to Industry Standards

• Executive compensation is benchmarked against a peer group of life sciences and related companies, including 10x Genomics, Bio-Techne, Certara, Cryoport, Guardant Health, Haemonetics, Maravai LifeSciences, Medpace Holdings, Myriad Genetics, Natera, NeoGenomics, Repligen, Sotera Health, Tandem Diabetes Care, and Twist Bioscience.
• The increase in threshold payout for the short-term incentive plan from 25% to 50% of target was implemented to align with prevalent market practice in the life sciences industry and enhance competitiveness.
• The adjustment of the Long-Term Incentive Plan (LTIP) mix to 50% PSUs and 50% time-based RSUs was made to better align with peers and market practice in the life sciences sector.
• The Relative TSR comparison group for PSUs includes 22 companies, comprising established compensation peers and other life sciences companies with similar market capitalization (~0.2x to 3.0x) and revenue (~0.3x to 2.0x), and with a strong TSR correlation to Azenta.
• The company's three-year average burn rate of 1.18% for fiscal years 2023-2025 is a metric often compared against industry averages to assess equity dilution and ensure prudent equity management.

Management Changes

Corporate Governance

Related Party Transactions

• As of September 30, 2025, there were no related party transactions since the beginning of the last fiscal year that would require disclosure under SEC rules.

Stakeholder Impact

• Shareholders: Direct impact through director elections, advisory vote on executive compensation, and the proposed increase in shares for the equity incentive plan. Financial performance and strategic updates aim to create long-term value. The clawback policy reinforces accountability.
• Employees: The equity incentive plan aims to attract, motivate, and retain talent. Compensation program changes and focus on talent development and well-being are highlighted.
• Customers: The company's mission to enable life sciences organizations to bring breakthroughs to market faster implies a positive impact through improved products and services.
• Management: Executive compensation is tied to financial and strategic goals, with clawback provisions for accountability, influencing management's focus and performance.

Next Steps

• Shareholders will vote on the election of ten directors at the Annual Meeting on January 28, 2026.
• Shareholders will cast an advisory vote on executive compensation at the Annual Meeting.
• Shareholders will vote on the approval of an amendment to the 2020 Equity Incentive Plan to increase shares by 2,750,000 at the Annual Meeting.
• Shareholders will ratify PricewaterhouseCoopers LLP as the independent registered accounting firm for FY2026 at the Annual Meeting.
• Management will continue to implement and oversee remediation plans for identified material weaknesses in internal control over financial reporting throughout fiscal year 2026.
• The Human Resources and Compensation Committee will seek to recover the remaining $34,361 of erroneously awarded compensation from Covered Executives in FY2026.
• If the equity plan amendment is approved, the company intends to file a registration statement with the SEC covering the 2,750,000 additional authorized shares.

Key Dates

Recommendation

The company demonstrated solid fiscal 2025 performance with revenue growth, significant margin expansion, and improved free cash flow, indicating effective business simplification and execution. The strategic divestiture of the B Medical business and focus on core life sciences segments are positive for future profitability. However, the 0% achievement on the prior three-year LTIP and the identified material weaknesses in internal controls, leading to a clawback, introduce a degree of uncertainty and suggest ongoing operational and financial reporting challenges. While the new executive compensation structure and board governance are robust, a 'hold' recommendation is appropriate until the remediation of internal control weaknesses is fully demonstrated and the long-term incentive plans show consistent achievement.

Keywords

Azenta, proxy statement, SEC filing, corporate governance, executive compensation, equity incentive plan, director election, financial performance, life sciences, sample management, multiomics, internal controls, clawback, shareholder meeting, Nasdaq, PricewaterhouseCoopers, ESG